Ibrutinib: Indication of added benefit in one of three therapeutic indications

(Institute for Quality and Efficiency in Health Care) No added benefit proven for chronic lymphocytic leukaemia and Waldenström macroglobulinaemia. Certain patients with relapsed or refractory mantle cell lymphoma benefit from the drug.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news